Bio-Tech: PET to outpace SPECT market in coming years
The U.S. market for SPECT and PET systems will increase nearly six-fold over the next seven years as new products are introduced to the market, according to a Bio-Tech Systems report.
Combined U.S. sales of SPECT and PET totaled $1.2 billion in 2010, and are expected to rise to $6 billion by 2018, according to the Las Vegas-based research firm.
SPECT sales should increase from $758 million in 2010 to $1.68 billion in 2018 and PET sales should increase from $391.8 million in 2010 to $4.31 billion in 2018. PET sales will grow at a faster pace than SPECT because of new products as well as increases in volume of FDG procedures, according to Bio-Tech.
“Market growth will also result from higher prices of the new products. This influx of new products will help all segments of molecular imaging and create a good platform for continued growth for both SPECT and PET,” the firm noted in a release about the report. “One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.”
The “The US Market for SPECT and PET Radiopharmaceuticals” report included analysis of current and future radiopharmaceutical markets, emerging markets for new molecular imaging platforms, good growth prospects for new SPECT and PET radiopharmaceuticals and the effect of technetium supply instabilities on the SPECT market.
Combined U.S. sales of SPECT and PET totaled $1.2 billion in 2010, and are expected to rise to $6 billion by 2018, according to the Las Vegas-based research firm.
SPECT sales should increase from $758 million in 2010 to $1.68 billion in 2018 and PET sales should increase from $391.8 million in 2010 to $4.31 billion in 2018. PET sales will grow at a faster pace than SPECT because of new products as well as increases in volume of FDG procedures, according to Bio-Tech.
“Market growth will also result from higher prices of the new products. This influx of new products will help all segments of molecular imaging and create a good platform for continued growth for both SPECT and PET,” the firm noted in a release about the report. “One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.”
The “The US Market for SPECT and PET Radiopharmaceuticals” report included analysis of current and future radiopharmaceutical markets, emerging markets for new molecular imaging platforms, good growth prospects for new SPECT and PET radiopharmaceuticals and the effect of technetium supply instabilities on the SPECT market.